AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Novo Nordisk Uses Custom Azure Agents to Speed Clinical Insight Work
Microsoft says Novo Nordisk is deploying custom AI agents on Azure to accelerate clinical insight generation. The move shows how large pharma is increasingly building internal AI systems to handle research, evidence synthesis, and operational analysis.
AstraZeneca's AI Agent Bet Points to a New Model for Drug Discovery Automation
AstraZeneca is reportedly turning to an AI agent to reduce the time needed for drug discovery. The move suggests the industry is starting to shift from passive prediction tools to more autonomous systems that can plan, search, and iterate across discovery workflows.
Pharma’s AI Readiness Problem Is Shifting From Enthusiasm to Execution
Health Data Management’s look at preparing for AI in pharma research focuses on a practical but crucial issue: organizations need the right data, governance, and operating model before they can expect useful results. The piece arrives as the industry’s AI ambitions are rising faster than many teams’ ability to implement them.
FDA sets clearer pathways for AI drug development engagement
FDA engagement pathways for AI drug development could reduce uncertainty for companies using machine learning in discovery and development. The most important consequence may be regulatory clarity: a sign that agencies are trying to meet AI-driven pharma innovation with more structured interaction models.
Novo Nordisk’s OpenAI partnership shows drug discovery is becoming an AI arms race
Novo Nordisk’s reported partnership with OpenAI highlights how drugmakers are widening their AI ambitions beyond internal tools and into platform-scale collaborations. The deal reflects a broader shift: competitive advantage in pharma may increasingly depend on access to frontier AI capabilities, not just proprietary biology.
Novo Nordisk’s OpenAI Deal Reflects Pharma’s Shift From Pilots to Core AI Strategy
Novo Nordisk’s move to work with OpenAI reflects how quickly pharma is shifting from experimental AI projects to strategic enterprise partnerships. The deal is less about a single model and more about how drugmakers want to redesign discovery around AI-enabled workflows.
Insilico’s Pharma.AI Event Highlights the Industry’s Shift From AI Pilots to Platform Strategy
Insilico Medicine’s Pharma.AI Spring Kickoff reflects a wider transformation in drug discovery: AI is increasingly being treated as a platform rather than a point solution. The event underscores how companies are trying to move from isolated applications to integrated intelligence across the entire R&D workflow.
FAIR Data Is Emerging as Pharma’s Real AI Bottleneck
Fierce Pharma’s focus on a FAIR data playbook for trustworthy AI highlights a growing industry realization: better models will not compensate for fragmented, poorly governed data. The story is significant because it reframes trustworthy AI in pharma as a data architecture challenge before it becomes a model validation challenge.
Merck’s KERMT Signals Big Pharma’s Shift From AI Pilots to Foundation Models for Drug Discovery
Merck’s disclosure of its KERMT model offers a clearer view into how major drugmakers are building proprietary AI systems tuned for chemistry and biology workflows. The significance is less the branding of one model than the evidence that large pharma increasingly sees internal foundation models as strategic R&D infrastructure.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.